Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?

Basit Öğe Kaydı
dc.authoridAktas, Burak Yasin/0000-0001-5460-4895
dc.authoridGUNER, GURKAN/0000-0003-2275-1158
dc.authorwosidAktas, Burak Yasin/AAA-4726-2022
dc.authorwosidÖztürk, Akın/JDC-7905-2023
dc.authorwosidCoşkun, Hasan Şenol/C-2070-2016
dc.authorwosidTatlı, Ali Murat/D-9111-2018
dc.authorwosidYumuk, Perran Fulden/A-6189-2018
dc.authorwosidGUNER, GURKAN/I-9062-2013
dc.contributor.authorGuner, Gurkan
dc.contributor.authorAktas, Burak Yasin
dc.contributor.authorBasal, Fatma Bugdayci
dc.contributor.authorDemirkazik, Ahmet
dc.contributor.authorGursoy, Pinar
dc.contributor.authorDemirci, Umut
dc.contributor.authorErman, Mustafa
dc.date.accessioned2024-06-12T11:09:27Z
dc.date.available2024-06-12T11:09:27Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurposeAnaplastic lymphoma kinase (ALK) mutations occurs in approximately 3-5% of patients with non-small cell lung cancer (NSCLC). Pleural involvement/effusion is common in ALK-positive patients with NSCLC at baseline. The aim of the study was to evaluate the characteristics of ALK-positive patients who have Ple-I/E.MethodsIn this multicenter study, patients with ALK-positive NSCLC who have Ple-I/E were retrospectively analyzed. Clinical and demographic characteristics of the disease, response rates, median progression-free survival (PFS), and overall survival (OS) were evaluated in 362 ALK-positive patients with NSCLC.ResultsOf the patients, 198 (54.7%) were male. The median age at the time of diagnosis was 54 (range 21-85) years. All patients' histology was adenocarcinoma (100%). At baseline, 57 (15.7%) patients had Ple-I/E. There was no association between Ple-I/E and gender, lung metastasis, or distant lymphadenopathy (LAP) metastasis. The frequencies of liver, brain, and bone metastases were significantly higher in ALK-positive patients without Ple-I/E compared to those with Ple-I/E (respectively 18.2% vs 4.8%, p = 0.008; 19.1% vs 4.8%, p = 0.001; 20.6% vs 8.9%, p = 0.002). The median PFS was longer in ALK-positive patients who had Ple-I/E (18.7 vs 10.6 months, p = 0.017). Similarly, the median OS was longer in ALK-positive patients who had Ple-I/E (44.6 vs 22.6 months, p = 0.051).ConclusionBrain, liver, and bone metastases were lower in ALK-positive patients with Ple-I/E. Patients presented with Ple-I/E were prone to have better PFS and OS.en_US
dc.identifier.doi10.1007/s00432-023-05190-3
dc.identifier.endpage13277en_US
dc.identifier.issn0171-5216
dc.identifier.issn1432-1335
dc.identifier.issue14en_US
dc.identifier.pmid37480524en_US
dc.identifier.scopus2-s2.0-85165876962en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage13271en_US
dc.identifier.urihttps://doi.org/10.1007/s00432-023-05190-3
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22796
dc.identifier.volume149en_US
dc.identifier.wosWOS:001034599600004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Cancer Research And Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNSCLCen_US
dc.subjectALK-Positiveen_US
dc.subjectPleural Involvementen_US
dc.subjectPleural Effusionen_US
dc.subjectPrognosisen_US
dc.subjectCell Lung-Canceren_US
dc.subjectBrain Metastasesen_US
dc.subjectSurvivalen_US
dc.subjectChemotherapyen_US
dc.subjectCrizotiniben_US
dc.subjectIdentificationen_US
dc.subjectGeneen_US
dc.titleIs there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu